RTOG-1306

Terminated

Return to Protocol Table

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator

Ramaswamy Govindan

Status

Terminated

Open to Accrual

November 4, 2013

Closed to Accrual

December 20, 2017

Terminated

June 4, 2018


Disease Site

Lung [LU] Non-small Cell Lung Cancer

Phase

II

Developmental Therapeutics

No

Primary Objective

To assess whether patients with unresectable local-regionally advanced NSCLC treated with targeted agents based on molecular characteristics have a longer progression-free survival than those treated with standard care therapy alone

Patient Population

Histologically or cytologically confirmed non-squamous NSCLC; unresectable stage IIIA or IIIB disease; patients must be surgically staged to confirm N2 or N3 disease.

Target Accrual

234

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.


Patient Study Webpage

There is no available patient study webpage available for this trial at this time.